Pancreatic Cancer Research

ResearcherThe University of SydneyActive in the last 2 years

Charbel Sandroussi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0005-1644-8170; OpenAlex author ID A5001467463. Sources: OpenAlex.

Their work

Papers
11 (first author 0, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
27
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: 3 papers · 2020: none · 2021: 3 papers · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 11

  1. Sarcopenia as a Marker of Immunometabolic Vulnerability in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/cancers18081205↗
  2. Portal venous circulating tumor cells as a biomarker for relapse prediction in resected pancreatic cancer. Co-author DOI 10.1007/s00018-025-05669-x↗
  3. A first-in-class pan-lysyl oxidase inhibitor impairs stromal remodeling and enhances gemcitabine response and survival in pancreatic cancer. Co-author DOI 10.1038/s43018-023-00614-y↗
  4. Genomic and Molecular Analyses Identify Molecular Subtypes of Pancreatic Cancer Recurrence. Co-author DOI 10.1053/j.gastro.2021.09.022↗
  5. Quality of Life Instruments and Trajectories After Pancreatic Cancer Resection: A Systematic Review. Last author DOI 10.1097/mpa.0000000000001896↗
  6. Real world outcomes of neoadjuvant chemotherapy and radiotherapy for borderline resectable pancreatic cancer: a multicentre observational study. Co-author DOI 10.1111/ans.17151↗
  7. ROR1 and ROR2 expression in pancreatic cancer. Co-author DOI 10.1186/s12885-021-08952-9↗
  8. Monitoring quality of care for patients with pancreatic cancer: a modified Delphi consensus. Co-author DOI 10.1016/j.hpb.2018.08.016↗
  9. Postoperative outcomes in elderly patients undergoing pancreatic resection for pancreatic adenocarcinoma: A systematic review and meta-analysis. Last author DOI 10.1016/j.ijsu.2019.09.030↗
  10. CAF hierarchy driven by pancreatic cancer cell p53-status creates a pro-metastatic and chemoresistant environment via perlecan. Co-author DOI 10.1038/s41467-019-10968-6↗
  11. A systematic review and meta-analysis of survival and surgical outcomes following neoadjuvant chemoradiotherapy for pancreatic cancer. Last author DOI 10.1007/s11605-011-1659-7↗

Closest collaborators

The 25 strongest of 27 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Mukund Karthik · 1 shared paper, 2026 · strength 0.39
  2. Peter Grimison · 2 shared papers, 2021–2025 · strength 0.34
  3. Dannel Yeo · 1 shared paper, 2025 · strength 0.21
  4. John E.J. Rasko · 1 shared paper, 2025 · strength 0.21
  5. Jaswinder Singh Samra · 2 shared papers, 2019–2021 · strength 0.20
  6. Neil Donald Merrett · 2 shared papers, 2019–2021 · strength 0.20
  7. Clare Toms · 1 shared paper, 2021 · strength 0.17
  8. Andrew Ohyama Parsonson · 1 shared paper, 2021 · strength 0.13
  9. George Hruby · 1 shared paper, 2021 · strength 0.13
  10. Anubhav Mittal · 1 shared paper, 2021 · strength 0.13
  11. Elinor Tan · 1 shared paper, 2019 · strength 0.11
  12. David Goldstein · 1 shared paper, 2019 · strength 0.07
  13. Rachel Ε. Neale · 1 shared paper, 2019 · strength 0.07
  14. James G. Kench · 1 shared paper, 2019 · strength 0.07
  15. Jennifer A. M. Philip · 1 shared paper, 2019 · strength 0.07
  16. Koroush Shahsavar Haghighi · 1 shared paper, 2019 · strength 0.07
  17. Ashika D. Maharaj · 1 shared paper, 2019 · strength 0.07
  18. Lorraine A. Chantrill · 1 shared paper, 2019 · strength 0.07
  19. John Raymond Zalcberg · 1 shared paper, 2019 · strength 0.07
  20. Liane Ioannou · 1 shared paper, 2019 · strength 0.07
  21. Charles H. C. Pilgrim · 1 shared paper, 2019 · strength 0.07
  22. Sue Evans · 1 shared paper, 2019 · strength 0.07
  23. Kate White · 1 shared paper, 2019 · strength 0.07
  24. Mehrdad Nikfarjam · 1 shared paper, 2019 · strength 0.07
  25. Daniel Gerald Croagh · 1 shared paper, 2019 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.